Exemestane: A milestone against breast cancer
Rapid advances in the treatment of breast cancer, especially in the form of hormone therapy have truly increased the hope of longer and better disease-free survival for these patients. Exemestane, a third generation aromatase inhibitor has been extensively evaluated in metastatic as well as adjuvant...
Main Authors: | Shetty Y, Chakkarwar P, Acharya S, Rajadhyaksha V |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2007-01-01
|
Series: | Journal of Postgraduate Medicine |
Subjects: | |
Online Access: | http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2007;volume=53;issue=2;spage=135;epage=138;aulast=Shetty |
Similar Items
-
Neoadjuvant endocrine treatment of women with breast cancer
by: Julian Iturbe, et al.
Published: (2011-09-01) -
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
by: Nobuaki Sato, et al.
Published: (2019-09-01) -
Prognostic Impact of Menopausal Hormone Therapy in Breast Cancer Differs According to Tumor Characteristics and Treatment
by: Christopher Godina, et al.
Published: (2020-02-01) -
Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial
by: Inmaculada Conejo, et al.
Published: (2018-06-01) -
Is the extension of adjuvant hormone therapy for breast cancer justified?
by: V. F. Semiglazov, et al.
Published: (2020-07-01)